(2024). Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records. Bmj Open Diabetes Res Care, 12. http://doi.org/10.1136/bmjdrc-2023-003548
. *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
(2023). Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the CPRD. Bmj Open, 13, e064541. http://doi.org/10.1136/bmjopen-2022-064541
. (2023). Polypharmacy and antidepressant acceptability in comorbid depression and type 2 diabetes: a cohort study using UK primary care data. Br J Gen Pract, 73, e392-e398. http://doi.org/10.3399/bjgp.2022.0295
. (2023). Characterising the burden of chronic kidney disease among people with type 2 diabetes in England: a cohort study using the Clinical Practice Research Datalink. Bmj Open, 13, e065927. http://doi.org/10.1136/bmjopen-2022-065927
. (2021). Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab, 23, 75-85. http://doi.org/10.1111/dom.14189
.